From Lab to Life: Safety, Regulatory Pathways and Clinical Trials in PCOS Nanomedicine

Polycystic Ovary Syndrome, commonly known as PCOS, is an intricate and multifaceted endocrine disorder that, in general, affects women at a reproductive age worldwide. Even though there have been some pharmacological advancements, the disorder still remains a challenge due to its complexities and heterogeneities which mostly lead to suboptimal clinical efficacy and the occurrence of negative side effects of the treatment. Consequently, treating PCOS with the resort of nanomedicine, which is nonetheless an attractive yet patient-friendly therapy of easy application, has been designed to treat PCOS. The present chapter charts out the whole transition of nanomedicine for PCOS starting with the bench-to-bedside innovation process. It discusses the preclinical safety testing of liposomes, polymeric nanoparticles, dendrimers, and nanogels that have been loaded with either plant-derived or synthetic drugs. There is also considerable attention given to preclinical toxicological assessment, and regulatory permission difficulties, as well as the standardization obstacles that could arise in the journey towards clinical validation. A comparative analysis of international regulatory bodies (FDA, EMA, and CDSCO) is intended to highlight the emerging guidelines and requirements of nanoformulations in the area of gynecological disorders. A comprehensive review of current and completed clinical trials indicates the extent of readiness for the PCOS nanomedicine to get into the mainstream. The future holds the promise of artificial intelligence (AI) based screening models, nano pharmacovigilance, and patient-centric delivery systems. The chapter is fully committed to conducting a thorough investigation while accompanied by four tables and three illustrations that provide a roadmap for researchers, clinicians, and regulatory scientists to make the nanomedicine innovation aimed at PCOS a reality.